{"entity":{"id":"al-273","kind":"drug","name":"AL-273","aka":[],"tldr":"AL-273 is an experimental small molecule from Alaw Therapeutics, at a stage the company does not state for EGFR-driven tumours.","summary":"AL-273 is a small molecule from Alaw Therapeutics. A next-generation pan-mutant EGFR inhibitor designed to cover a broad range of clinically relevant EGFR mutations, including resistance-associated variants. The company does not state its stage; it is aimed at EGFR-driven tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Stage not stated on the pipeline page; no registered trial found, and the May 2026 release names only AL-605 as clinical. It has not been shown to work in people.","asOf":"2026-11-03","links":[{"label":"Alaw Therapeutics: alawtx.com","url":"https://www.alawtx.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["alaw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AL-273","modality":"Small molecule","mechanism":"A next-generation pan-mutant EGFR inhibitor designed to cover a broad range of clinically relevant EGFR mutations, including resistance-associated variants.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/al-273/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"alaw-therapeutics","kind":"company","name":"Alaw Therapeutics","route":"/companies/alaw-therapeutics/"}]}}